Several pharmacological approaches aimed at suppressing the reactivity and the harmful actions of microglia in AD have been elucidated, including the use of such broadly acting medicines as non-steroidal anti-inflammatory drugs as well as biologics targeting specific inflammatory mechanisms, including the tumor necrosis factor (TNF)-neutralizing etanercept; however, these approaches have not produced clinically significant beneficial results [5,6]. Here, TNF is linked to Alzheimer disease.